The ESMO Advanced Course on the Evolving Role of CDK4/6 Inhibitors in Hormone Receptor Positive HER2 Negative Early and Advanced Breast Cancer 2026: Beijing is an intensive educational symposium scheduled for March 27–28, 2026, in Beijing, China.

Co-chaired by Giuseppe Curigliano and Binghe Xu, this 1.5-day course is specifically designed for experienced oncologists and oncology specialists to deepen their understanding of CDK4/6 inhibition in both early and metastatic HR+/HER2- breast cancer settings. The course is accredited with 11 ESMO-MORA category 1 points, serving as a vital platform for clinicians in the Asia-Pacific region to integrate the latest evidence into precision breast cancer management.

Application.